Jessica Schmit, MD
Medical Oncology · Gainesville, FLNPI 1659692762
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for medical oncology clinicians in FL, where the typical reported total is $8,890.
Across 42 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$212
- E.r. Squibb & Sons, L.L.C.$150
- AstraZeneca$89
- Regeneron Healthcare Solutions, Inc.$79
- Pfizer$61
- EMD Serono, Inc.$48
- plus $354 from 14 others
Across 3 payments — averaging $24,074 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$39K
- AbbVie$34K
What the payments were for
- Food & beverage$95096%
- Education$434%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 7 | $212 |
| E.r. Squibb & Sons, L.L.C. | 7 | $150 |
| AstraZeneca | 3 | $89 |
| Regeneron Healthcare Solutions, Inc. | 3 | $79 |
| Pfizer | 3 | $61 |
| EMD Serono, Inc. | 2 | $48 |
| Bristol Myers Squibb | 2 | $45 |
| GSK | 2 | $42 |
| Gilead | 2 | $40 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Springworks Therapeutics, Inc. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Array Biopharma Inc | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| AbbVie | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Merck | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Fennec Pharmaceuticals, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $15 |
How this compares
$993 in reported general payments places this provider in the 15th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Gainesville
- John WingardGainesville$106K
- Vijay PatelGainesville$72K
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.